November 2025 highlights FDA approvals for denosumab and pertuzumab biosimilars, enhancing competition and access in oncology and bone health markets.

In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...

Biosimilar denosumab offers significant cost savings and improved access to treatment, alleviating financial burdens in ...

New research reveals that switching from originator to biosimilar adalimumab for hidradenitis suppurativa may lead to reduced ...

Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...

FDA approves Poherdy, the first interchangeable biosimilar for pertuzumab (Perjeta), enhancing competition in HER2-positive ...

Patients with Crohn disease report high satisfaction and minimal discomfort using the citrate-free biosimilar CT-P17, enhancing adherence to treatment.